Frontage Holdings Corporation (HKG:1521)
1.000
+0.010 (1.01%)
May 7, 2026, 1:45 PM HKT
Frontage Holdings Revenue
In the year 2025, Frontage Holdings had annual revenue of $256.69M USD with 0.70% growth. Frontage Holdings had revenue of $130.11M in the half year ending December 31, 2025, a decrease of -1.05%.
Revenue
$256.69M
Revenue Growth
+0.70%
P/S Ratio
1.01
Revenue / Employee
$168.54K
Employees
1,523
Market Cap
2.03B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 256.69M | 1.78M | 0.70% |
| Dec 31, 2024 | 254.91M | -4.95M | -1.90% |
| Dec 31, 2023 | 259.86M | 9.50M | 3.79% |
| Dec 31, 2022 | 250.36M | 65.92M | 35.74% |
| Dec 31, 2021 | 184.44M | 58.63M | 46.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.45B |
| AIM Vaccine | 1.30B |
| Mabpharm | 718.98M |
| Medtide | 634.40M |
| Cutia Therapeutics | 374.07M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 171.70M |
| Beijing Biostar Pharmaceuticals | 37.13M |
| Kintor Pharmaceutical | 36.37M |